Bioptigen moves headquarters to new, expanded facility
Optical coherence tomography (OCT) systems maker Bioptigen is relocating its headquarters to a larger facility in Research Triangle Park.
Optical coherence tomography (OCT) systems maker Bioptigen (Research Triangle Park, NC) is relocating its headquarters to a larger facility in Research Triangle Park. The move will reportedly accommodate expanded production of the company's Envisu ophthalmic OCT system, which the FDA cleared for use in patients earlier this year. The system is also cleared for commercialization in Canada, Europe, and Australia.
At its new home in Keystone Technology Park, the company will double the size of its current facility footprint as well as its research and development activities. The company also has doubled the size of its staff within the last two years, and Dr. Eric Buckland, president and CEO, says he anticipates hiring even more employees to meet operational demands.
Envisu is the only commercially available OCT system of its kind in the US that provides handheld imaging of patients ranging from premature infants to adults, whether they are upright or supine, ambulatory or confined, conscious or sedated.
Also, the National Institutes of Health (NIH; Bethesda, MD) recently awarded the company with a grant to continue investigation of ophthalmic imaging solutions for premature and neonatal infants.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Laser Focus World has gone mobile: Get all of the mobile-friendly options here.
Subscribe now to BioOptics World magazine; it's free!